Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now displays a newer revision tag: Revision: v3.5.4, replacing the prior v3.5.3.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe page's revision changed from v3.5.2 to v3.5.3, indicating a small backend update. It reflects an internal version bump rather than a change to the displayed study information.SummaryDifference0.0%

- Check41 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check69 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check84 days agoChange DetectedRevision: v3.4.3 implemented. No visible changes to study data, eligibility criteria, or study details.SummaryDifference0.0%

- Check105 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2; no study data or page functionality appears to be altered.SummaryDifference0.0%

Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.